Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Cubicin
Active Ingredient: Daptomycin 350mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Catalent Pharma Solutions LLC, Albuquerque, New Mexico, United States of America
Product: Cubicin
Active Ingredient: Daptomycin 500mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturers: Catalent Pharma Solutions LLC, Albuquerque, New Mexico, United States of America
Hospira, Inc., McPherson, Kansas, United States of America
Product: Norprolac
Active Ingredients: Quinagolide hydrochloride 0.0273mg equivalent to 0.025mg quinagolide
Quinagolide hydrochloride 0.0546mg equivalent to 0.05mg quinagolide
Dosage Form: Tablet
New Zealand Sponsor: Pharmaco (NZ) Limited
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
Product: Norprolac
Active Ingredient: Quinagolide hydrochloride 0.1638mg equivalent to quinagolide 0.15mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmaco (NZ) Limited
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
Product: Norprolac
Active Ingredient: Quinagolide hydrochloride 0.0819mg equivalent to quinagolide 0.075mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmaco (NZ) Limited
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
Dated this 28th day of August 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).